The Medicines and Healthcare products Regulatory Agency (MHRA) has warned women using GLP-1 receptor agonists (GLP-1RAs) for weight loss to use effective contraception. The agency is concerned that some patients are obtaining these drugs from unregulated sources, where important safety information may be missing.
GLP-1RAs were first created to treat type 2 diabetes but have recently become popular for weight loss. However, the MHRA stressed that these drugs can pose risks to pregnant women and their unborn babies.
Reports show that some people are accessing these medications without proper medical supervision. This raises worries that users may not be fully aware of the dangers.
The MHRA urged anyone considering GLP-1RA treatment to speak with a healthcare professional. They should be informed about the risks and the need for reliable contraception while using these drugs.
